Professional Football Compensation Committee

Gulf Resources Announces Management Changes

Retrieved on:

Thursday, November 16, 2023

Annual general meeting, Compensated emancipation, Bromine, Growth, Professional Football Compensation Committee, Management

SHOUGUANG, China, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gulf Resources, Inc. (Nasdaq:GURE) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, recently disclosed proposed management changes to come into effect during the Company’s annual meeting of shareholders which is to be hold on November 30, 2023 (the “Annual Meeting”), in a Form 8-K filed with the SEC on October 3, 2023.

Key Points:

SHOUGUANG, China, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gulf Resources, Inc. (Nasdaq:GURE) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, recently disclosed proposed management changes to come into effect during the Company’s annual meeting of shareholders which is to be hold on November 30, 2023 (the “Annual Meeting”), in a Form 8-K filed with the SEC on October 3, 2023.
This information was reiterated to ensure shareholders were informed, given the possibility that some may have missed the initial 8-K filing.
Mr. Yang remarked, "I take pride in the team we have cultivated at Gulf Resourced, guided by Mr. Liu Xiaobin's leadership.
Expressing gratitude, Mr. Liu stated, "I extend my appreciation to Mr. Yang for his mentorship and backing in shaping Gulf Resources.

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Retrieved on:

Thursday, November 16, 2023

Therapy, Patient, Retina, Employment, Professional Football Compensation Committee, Compensated emancipation, Pharmaceutical industry

The Company granted stock options to purchase up to an aggregate of 15,000 shares of EyePoint Pharmaceuticals common stock to five new employees.

Key Points:

The Company granted stock options to purchase up to an aggregate of 15,000 shares of EyePoint Pharmaceuticals common stock to five new employees.
The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4).
The option awards have an exercise price of $6.69 per share, the closing price of EyePoint Pharmaceuticals’ common stock on November 15, 2023.
Vesting of the options is subject to the employee’s continued service with EyePoint Pharmaceuticals through the applicable vesting dates.

Mama’s Creations Appoints Lynn L. Blake to Board of Directors

Retrieved on:

Tuesday, November 14, 2023

Volunteers of America, Audit committee, Honeywell, Carlson School of Management, CFO, University, Finance, Accounting, Volunteering, Compensated emancipation, MBA, CPA, BBA, Professional Football Compensation Committee, Management

EAST RUTHERFORD, NJ, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, today announced the appointment of veteran finance leader Lynn L. Blake to its Board of Directors. Lynn will also serve as Chair of the Board’s Audit Committee.

Key Points:

Lynn brings over 30 years of financial leadership and public market experience to the Mama’s Creations Board, including Chief Financial Officer experience at multiple publicly traded companies, a private equity-owned portfolio company, and a venture-backed startup.
Currently, Lynn serves in Board roles at The trū Shrimp Companies, Elire, Inc., Volunteers of America and the CFO Leadership Council.
At The trū Shrimp Companies, Lynn is Chair of the Audit Committee and serves on the Compensation Committee.
I look forward to working closely with Adam and the Board as they continue their rapid pace of operational execution in this attractive, fast-growing category.”

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Retrieved on:

Monday, November 13, 2023

Employment, RSU, Patient, Obesity, Compensated emancipation, Polyphagia, Professional Football Compensation Committee, MC4R, Pharmaceutical industry

These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").

Key Points:

These inducement stock options and inducement RSUs are subject to the terms of the Rhythm Pharmaceuticals, Inc. 2022 Employment Inducement Plan (the "Inducement Plan").
The Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to the employees entering into employment with Rhythm pursuant to Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan was adopted by Rhythm’s board of directors on February 9, 2022.
The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the applicable date of hire, subject to each such employee’s continued employment on each vesting date.

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Friday, November 10, 2023

Therapy, Employment, Professional Football Compensation Committee, Compensated emancipation, Pharmaceutical industry

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees.

Key Points:

REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two new employees.
The Compensation Committee, consisting of independent members of the Board of Directors of Soleno, approved the grant of non-qualified stock options to purchase 145,000 shares of common stock to two employees, as an inducement for them entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $21.93 per share, which is equal to the closing price of Soleno’s common stock on the Nasdaq Stock Market on November 8, 2023, the date of grant.
The option awards are subject to the terms and conditions of Soleno’s existing 2020 Inducement Equity Incentive Plan and the terms and conditions of the stock option covering the grant.

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Saturday, December 9, 2023

Biotechnology, Pharmaceutical, Health, RSU, Spiroplasma mirum, Employment, Professional Football Compensation Committee, Medication, Compensated emancipation

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,750 shares of common stock and 12,880 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan.

Key Points:

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 8, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,750 shares of common stock and 12,880 restricted stock units (“RSUs”) to five new employees under Mirum’s 2020 Inducement Plan.
The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years, with 33% of the underlying shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employees’ continued service relationship with Mirum through the applicable vesting dates.
The awards are subject to the terms and conditions of Mirum’s 2020 Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Retrieved on:

Friday, December 1, 2023

Biotechnology, Pharmaceutical, Health, Oncology, Employment, Compensated emancipation, Professional Football Compensation Committee

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.

Key Points:

Forte Biosciences, Inc. ( www.fortebiorx.com ) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte’s Board of Directors approved the grant of an equity award to purchase 25,000 shares of common stock to a new non-executive employee as a material inducement to such individual’s accepting employment with the Company, with such award vesting over four years, with twenty-five percent vesting on the one-year anniversary of the grant date and the remaining seventy-five percent vesting in equal monthly increments over the succeeding thirty-six months, subject to the individual’s continuous employment through each vesting date.
The Inducement Award was made under Forte’s 2020 Inducement Equity Incentive Plan and related award agreements and will have terms and conditions generally consistent with those of Forte’s 2021 Equity Incentive Plan.

Yelp Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Retrieved on:

Monday, November 20, 2023

Apps, Applications, Technology, Marketing, Communications, Internet, Digital Marketing, Social Media, Retail, Online Retail, Yelp, NYSE, Employment, Inc., Compensated emancipation, NYSE Listed Company Manual, Professional Football Compensation Committee, Pharmaceutical industry

Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on November 14, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 36,354 shares of Yelp’s common stock to eight new non-executive employees to induce them to accept employment with Yelp.

Key Points:

Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on November 14, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 36,354 shares of Yelp’s common stock to eight new non-executive employees to induce them to accept employment with Yelp.
Each award was granted under the Yelp Inc. 2023 Inducement Award Plan and vests over a four-year period, subject to continued employment with Yelp through each vesting date.
Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on:

Wednesday, November 15, 2023

Biotechnology, Health, Oncology, RSU, Employment, Helmy Eltoukhy, Compensated emancipation, Professional Football Compensation Committee

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units (“RSUs”) representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”).

Key Points:

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on November 8, 2023, the Compensation Committee of Guardant’s Board of Directors granted restricted stock units (“RSUs”) representing 50,741 shares of its common stock to 43 new non-executive employees under the Guardant Health, Inc. 2023 Employment Inducement Incentive Award Plan (the “Inducement Plan”).
The RSUs were granted as inducements material to the employees entering into employment with Guardant in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Guardant, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant, pursuant to Nasdaq Listing Rule 5635(c)(4).
The RSUs are subject to the terms and conditions of the Inducement Plan and the terms and conditions of a RSU award agreement covering the grant.

Lattice Semiconductor Appoints John Forsyth and Que Thanh Dallara to Board of Directors

Retrieved on:

Tuesday, November 14, 2023

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced the appointment of Que Thanh Dallara and John Forsyth to the Company’s Board of Directors effective November 14, 2023.

Key Points:

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced the appointment of Que Thanh Dallara and John Forsyth to the Company’s Board of Directors effective November 14, 2023.
Mr. Forsyth will also serve as a member of the Nominating and Governance Committee and Ms. Dallara will serve as a member of the Compensation Committee.
Ms. Dallara brings to the Company over 20 years of general management and enterprise transformation experience in multiple industries globally.
We look forward to John and Que’s contributions as Lattice continues to execute on its long-term growth strategy.”